Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Alexander J. Rossi; Tahsin M. Khan; Hanna Hong; Gregory B. Lesinski; Christina Wu; Jonathan M. Hernandez

doi:10.1245/s10434-021-10111-0

Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Alexander J. Rossi
, Tahsin M. Khan
, Hanna Hong
, Gregory B. Lesinski
, Christina Wu
, Jonathan M. Hernandez

Center for Clinical and Translational Science

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	4098-4099
Number of pages	2
Journal	Annals of Surgical Oncology
Volume	28
Issue number	8
DOIs	https://doi.org/10.1245/s10434-021-10111-0
State	Published - Aug 2021

Access to Document

10.1245/s10434-021-10111-0

Cite this

@article{de648b03dea6428992d32f045edfb23e,

title = "Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer",

author = "Rossi, \{Alexander J.\} and Khan, \{Tahsin M.\} and Hanna Hong and Lesinski, \{Gregory B.\} and Christina Wu and Hernandez, \{Jonathan M.\}",

note = "Funding Information: Gregory Lesinski received funding via sponsored research agreements through Emory University for research from Vaccinex. The remaining authors have no conflicts of interest. ",

year = "2021",

month = aug,

doi = "10.1245/s10434-021-10111-0",

language = "English",

volume = "28",

pages = "4098--4099",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

number = "8",

}

TY - JOUR

T1 - Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

AU - Rossi, Alexander J.

AU - Khan, Tahsin M.

AU - Hong, Hanna

AU - Lesinski, Gregory B.

AU - Wu, Christina

AU - Hernandez, Jonathan M.

N1 - Funding Information: Gregory Lesinski received funding via sponsored research agreements through Emory University for research from Vaccinex. The remaining authors have no conflicts of interest.

PY - 2021/8

Y1 - 2021/8

UR - https://www.scopus.com/pages/publications/85105885037

U2 - 10.1245/s10434-021-10111-0

DO - 10.1245/s10434-021-10111-0

M3 - Letter

C2 - 33987757

AN - SCOPUS:85105885037

SN - 1068-9265

VL - 28

SP - 4098

EP - 4099

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 8

ER -

Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Access to Document

Other files and links

Cite this